TY - JOUR
T1 - Role of high-dose chemotherapy with autologous stem-cell rescue in men with previously treated germ cell tumors
AU - Pagliaro, Lance C.
PY - 2017/4/1
Y1 - 2017/4/1
N2 - A 39-year-old, previously healthy man presented with a left testicular mass, confirmed on ultrasound. He underwent left inguinal orchiectomy, which disclosed testicular carcinoma composed of 90% choriocarcinoma, 9% seminoma, and 1% teratoma. Imaging revealed numerous metastases in the lungs, liver, and brain. Prechemotherapy levels of serum tumor markers were alpha-fetoprotein (AFP) 2.0 ng/mL, human chorionic gonadotropin (hCG) 151,111 IU/L, and lactate dehydrogenase 588 U/L. He received four courses of etoposide, ifosfamide, and cisplatin chemotherapy, given without bleomycin because of the anticipated need for postchemotherapy thoracic surgery. He had an incomplete response to induction chemotherapy. The serum hCG level was 8.1 IU/L, and there were residual lesions in the liver and lungs whereas the brain metastases had nearly resolved. His Eastern Cooperative Oncology Group performance status was zero.He had no symptoms of ototoxicity or peripheral neurotoxicity. Repeat serumhCG levels after chemotherapy were 12.3 IU/L at 2 weeks and 325 IU/L at 4 weeks. He was referred to discuss optimal ongoing treatment.
AB - A 39-year-old, previously healthy man presented with a left testicular mass, confirmed on ultrasound. He underwent left inguinal orchiectomy, which disclosed testicular carcinoma composed of 90% choriocarcinoma, 9% seminoma, and 1% teratoma. Imaging revealed numerous metastases in the lungs, liver, and brain. Prechemotherapy levels of serum tumor markers were alpha-fetoprotein (AFP) 2.0 ng/mL, human chorionic gonadotropin (hCG) 151,111 IU/L, and lactate dehydrogenase 588 U/L. He received four courses of etoposide, ifosfamide, and cisplatin chemotherapy, given without bleomycin because of the anticipated need for postchemotherapy thoracic surgery. He had an incomplete response to induction chemotherapy. The serum hCG level was 8.1 IU/L, and there were residual lesions in the liver and lungs whereas the brain metastases had nearly resolved. His Eastern Cooperative Oncology Group performance status was zero.He had no symptoms of ototoxicity or peripheral neurotoxicity. Repeat serumhCG levels after chemotherapy were 12.3 IU/L at 2 weeks and 325 IU/L at 4 weeks. He was referred to discuss optimal ongoing treatment.
UR - http://www.scopus.com/inward/record.url?scp=85016587012&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85016587012&partnerID=8YFLogxK
U2 - 10.1200/JCO.2016.70.6523
DO - 10.1200/JCO.2016.70.6523
M3 - Article
C2 - 27992270
AN - SCOPUS:85016587012
SN - 0732-183X
VL - 35
SP - 1036
EP - 1040
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 10
ER -